Medical/Pharmaceuticals
Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024
BARCELONA, Spain, Sept. 19, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place fromSeptember 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading...
2024-09-19 20:30
2206
NUS scientists discover novel approach to rejuvenate aged egg cells
Groundbreaking findings provide a proof-of-concept development of a
non-invasive cell-based method to improve the quality of eggs from older
females for IVF
SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Researchers from the Mechanobiology
Institute
2024-09-19 18:28
2877
MGI Tech partners with Dasa to enhance health diagnosis with genetic sequencing in Brazil
New technologies will contribute to performing genetic tests to diagnose cancers, rare diseases and other diseases with greater precision, advancing personalized medicine in the country SÃO PAULO, Brazil, Sept. 18, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building ...
2024-09-19 11:05
2457
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocell...
2024-09-19 09:00
6857
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
* ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. * Preliminary results from this 12-week study demonstrated that ISM001-055 possesses a favorable safety profile and dos...
2024-09-18 21:30
2240
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and rese...
2024-09-18 18:18
3084
TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging
HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and gr...
2024-09-18 16:00
3159
AI Plus Clinic Tamaplaza Enhances System to Provide Rapid Diagnosis and Peace of Mind with Remote Robots Starting September 2024
YOKOHAMA, Japan, Sept. 18, 2024 /PRNewswire/ -- - New System Integrates AI Technology and Home Healthcare Launched in July 2024 - AI Plus Clinic Tamaplaza, based in Aoba-ku, Yokohama, Kanagawa Prefecture, operating under Kouetsukai Medical Corporation, has announced a new medical system integra...
2024-09-18 14:00
1959
inHearing Technology Inc. Announced the Acquisition of Intricon's Hearing Health Business
ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- inHearing Technology Inc., a
wholly-owned subsidiary ofHuizhou Jinghao Medical Technology Co., Ltd.,
announced onSeptember 11, 2024, the acquisition of Intricon's Hearing Health
Business.
2024-09-18 10:27
3714
Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI
TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an Investigational New Drug (IND) application for Pidnarulex ...
2024-09-18 10:06
3253
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MOU with theUniversity of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters,...
2024-09-18 09:26
4003
Datasea's New 5G AI Multimodal Agreements Have Already Generated $9.0 Million of 5G-AI Services
Agreements Boost Fiscal 2025 Revenue and Expand Datasea's 5G Application Market Positioning inChina BEIJING, Sept. 17, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based company focused on innovative high-tech acoustics and 5G-Artificial Intelligence ("A...
2024-09-17 21:45
2851
See-Mode Technologies Receives FDA Clearance for Thyroid Ultrasound AI Analysis and Reporting Software
MELBOURNE, Australia, Sept. 17, 2024 /PRNewswire/ -- See-Mode Technologies, a global innovator in AI for ultrasound imaging, today announced the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their thyroid ultrasound analysis and reporting software. See-Mode's A...
2024-09-17 20:00
2841
Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics
Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...
2024-09-17 15:47
3206
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. ...
2024-09-17 00:01
2477
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...
2024-09-16 20:00
3453
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...
2024-09-16 19:00
3044
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024
* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...
2024-09-16 18:00
3406
Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The prelimina...
2024-09-16 15:35
5992
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or...
2024-09-15 15:10
4474
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 272 media titles]
2026-10-23 21:52
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
20208
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
19636
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
17570
